Now Live on OncLive: All 7 ESMO 2025 Review Episodes

Key Updates in Metastatic Uveal Melanoma

Watch the Full Series

OUR THERAPYClinical and Scientific Publications

Prospective Studies

Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma

2025 | Zager et al.

Read more

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma

2025 | Zager et al.

Read more

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

2024 | Zager et al.

Read more

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study

2020 | Meijer et al.

Read more

Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan

2017 | de Leede et al.

Read more

Cohort & Case Studies

Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

2025 | Laukhuf et al.

Read more

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis

2025 | Tong et al.

Read more

Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation

2024 | Veelken et al.

Read more

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience

2022 | Dewald et al.

Read more

New Perspectives in Unresectable Cholangiocarcinoma? Evaluation of Chemosaturation with Percutaneous Hepatic Perfusion as a Palliative Treatment Option

2022 | Dewald et al.

Read more

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma

2022 | Modi et al.

Read more

Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases

2021 | Bethlehem et al.

Read more

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden

2020 | Brüning et al.

Read more

Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma

2020 | Schönfeld et al.

Read more

Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience

2019 | Artzner et al.

Read more

Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease

2017 | Karydis et al.

Read more

Reviews

Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion

2025 | Padia et al.

Read more

Scientific Meetings

Melphalan/Hepatic Delivery System versus Best Available Care in Patients with Unresectable Metastatic Uveal Melanoma: Randomized FOCUS Trial Results

ASCO 2024 | Zager et al.

Read more

Subgroup Analysis of FOCUS Phase 3 Trial Efficacy Results

ESMO 2023 | Wheater et al.

Read more

FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A)

ASCO 2022 | Zager et al.

Read more

Isolated Hepatic Perfusion (IHP)

Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases

2025 | Olofsson Bagge et al.

Read more